Insilico Inks Exclusive License for Anti-Cancer Molecule
Insilico Medicine is revolutionizing drug discovery for mesothelioma and other solid tumors with its generative AI engine .
Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
Overview
Insilico's mission is to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence, significantly reducing the time and cost to bring life-saving medications to patients.
Insilico Medicine's Mission
A global clinical stage biotechnology company powered by generative AI, Insilico Medicine is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
At-a-Glance
Insilico's Pharma.AI platform provides end-to-end drug discovery and development services, including target discovery, novel drug design, and clinical trial outcome prediction and optimization.
The platform was used to develop Insilico's internal pipeline of 31 programs across 29 drug targets, five of which are clinical stage, and one, ISM001-055 for idiopathic pulmonary fibrosis (IPF), which is in Phase II trials.
Insilico is a global organization with headquarters in New York City and Hong Kong, and offices and labs in Montreal, Shanghai, Suzhou, and Abu Dhabi.
In the News
AI-Designed Therapy for Inflammatory Bowel Disease Advances
The successful treatment of patients with IBD, such as ulcerative colitis or Crohn's disease, might be transformed by Insilico’s ISM5411.
First AI-Designed Drug Improves IPF Lung Function
Insilico Medicine reports its investigational SM001-055 - the first drug designed using generative AI - had encouraging topline results in a phase 2A clinical trial.
Five Tips for Entrepreneurs from Alex Zhavoronkov, PhD, CEO of Insilico Medicine
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, — one of the world's top generative AI drug discovery companies, shares his top five tips for biotech startup entrepreneurs on how to maximize success.
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, to Address #GenAI4Pharma Showcase at Cure
Alex Zhavoronkov, PhD, CEO of Insilico Medicine, presents the keynote at the #GenAI4Pharma at Cure.
From Clinic to Climate: Insilico’s Alex Zhavoronkov Talks AI
Biotech Insilico Medicine aims to transform drug discovery and development using generative AI. that discovers novel targets, generates new molecules, and predicts clinical trial success.
